Trellus Health PLC Notice of Results (3715M)

TIDMTRLS

RNS Number : 3715M

Trellus Health PLC

14 September 2023

Trellus Health plc

("Trellus Health" or the "Company")

Notice of Results

Investor Presentation

LONDON, U.K. AND NEW YORK, U.S. (14 September 2023). Trellus Health plc (AIM: TRLS), which is commercializing a scientifically validated and clinically proven personalized resilience-driven self-management solution for chronic health conditions at their intersection with mental health, announces that it expects to report its interim results for the period ended 30 June 2023 on 28 September 2023.

Investor Presentation

Dr. Marla Dubinsky, CEO and Co-Founder, and Joy Bessenger, Chief Financial Officer, will provide a live presentation relating to the interim results via Investor Meet Company on 2 October 2023 at 17:00 BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Trellus Health plc via:

https://www.investormeetcompany.com/trellus-health-plc/register-investor

Investors who already follow Trellus Health plc on the Investor Meet Company platform will automatically be invited.

For further information please contact:

 
Trellus Health plc                                         https://trellushealth.com/ 
Dr. Marla Dubinsky, CEO and Co-Founder                                Via Walbrook PR 
Dr. Daniel Mahony Chairman 
 
Singer Capital Markets (Nominated                            Tel: +44 (0)20 7496 3000 
 Adviser and Broker) 
Aubrey Powell / Jen Boorer 
 
Walbrook PR                        Tel: +44 (0)20 7933 8780 or trellus@walbrookpr.com 
Paul McManus / Sam Allen /                  Mob: +44 (0)7980 541 893 / 0 7748 651 727 
 Phillip Marriage                                                     / 07867 984 082

About Trellus Health plc ( www.trellushealth.com )

Trellus Health (LSE: TRLS) is the first resilience-focused digital health company targeting the intersection of chronic illness and mental health. Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate(TM), a whole-person technology-enhanced experience that empowers individuals to master their health and results in relieving disease burden, building self-management skills and promoting positive health behaviours that improves outcomes and enables thriving in the face of a chronic condition.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both experts at treating and healing both the physical and emotional impacts of IBD and IBS and have been innovators for whole person healthcare for a combined 50 years.

The Company was initially focused on inflammatory bowel disease ("IBD"), which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis but has now added Irritable Bowel Syndrome ("IBS"). Given the common emotional and mental health struggles often experienced by individuals suffering from a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

The Trellus Elevate(TM) program incorporates the GRITT(TM) methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than five years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers. Patients with IBD managed with the proprietary resilience methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program which is a major indicator of improved health outcomes(1) .

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

(1) Source: https://www.sciencedirect.com/science/article/pii/S1542356521012258 )

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NORQXLFFXKLEBBZ

(END) Dow Jones Newswires

September 14, 2023 02:00 ET (06:00 GMT)

Trellus Health (LSE:TRLS)
過去株価チャート
から 3 2024 まで 4 2024